Log in

NASDAQ:NTRP - Neurotrope Stock Price, Forecast & News

$1.25
-0.18 (-12.59 %)
(As of 01/27/2020 04:23 AM ET)
Today's Range
$1.21
Now: $1.25
$1.38
50-Day Range
$0.78
MA: $1.04
$1.45
52-Week Range
$0.63
Now: $1.25
$8.40
Volume1.65 million shs
Average Volume2.81 million shs
Market Capitalization$16.34 million
P/E RatioN/A
Dividend YieldN/A
Beta1.98
Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTRP
CUSIPN/A
Phone973-242-0005

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.05 per share

Profitability

Net Income$-11,020,000.00

Miscellaneous

Employees6
Market Cap$16.34 million
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive NTRP News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter.


Neurotrope (NASDAQ:NTRP) Frequently Asked Questions

What is Neurotrope's stock symbol?

Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."

How were Neurotrope's earnings last quarter?

Neurotrope Inc (NASDAQ:NTRP) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.03. View Neurotrope's Earnings History.

When is Neurotrope's next earnings date?

Neurotrope is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Neurotrope.

What price target have analysts set for NTRP?

2 analysts have issued 1-year price objectives for Neurotrope's shares. Their forecasts range from $1.00 to $16.00. On average, they anticipate Neurotrope's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 580.0% from the stock's current price. View Analyst Price Targets for Neurotrope.

What is the consensus analysts' recommendation for Neurotrope?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurotrope in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Neurotrope.

What are Wall Street analysts saying about Neurotrope stock?

Here are some recent quotes from research analysts about Neurotrope stock:
  • 1. According to Zacks Investment Research, "Neurotrope, Inc. is focused primarily on the development and commercialization of Alzheimer's disease therapeutic products related diagnostics. The Company develops and markets two product platforms, including a non-invasive diagnostic test for Alzheimer's disease and a drug candidate called bryostatin for the treatment of Alzheimer's disease, both of which are in the clinical testing stage. Neurotrope, Inc. is based in Plantation, Florida. " (11/1/2019)
  • 2. Maxim Group analysts commented, "Neurotrope announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of Bryostatin-1 in acute lymphoblastic leukemia (ALL)." (2/5/2019)

Has Neurotrope been receiving favorable news coverage?

News headlines about NTRP stock have trended extremely negative on Monday, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Neurotrope earned a news sentiment score of -4.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Neurotrope.

Are investors shorting Neurotrope?

Neurotrope saw a decline in short interest in December. As of December 31st, there was short interest totalling 536,700 shares, a decline of 7.6% from the December 15th total of 580,600 shares. Based on an average daily volume of 272,500 shares, the short-interest ratio is currently 2.0 days. Approximately 5.5% of the shares of the stock are sold short. View Neurotrope's Current Options Chain.

Who are some of Neurotrope's key competitors?

What other stocks do shareholders of Neurotrope own?

Who are Neurotrope's key executives?

Neurotrope's management team includes the folowing people:
  • Dr. Charles S. Ryan, CEO & Director (Age 55)
  • Dr. Daniel L. Alkon, Pres & Chief Scientific Officer (Age 77)
  • Mr. Robert Weinstein, CFO, Exec. VP, Sec. & Treasurer (Age 59)
  • Dr. Michael Ciraolo, Gen. Counsel & COO (Age 46)
  • Mr. Jeffrey Benison, Director of Corp. Communications

How do I buy shares of Neurotrope?

Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Neurotrope's stock price today?

One share of NTRP stock can currently be purchased for approximately $1.25.

How big of a company is Neurotrope?

Neurotrope has a market capitalization of $16.34 million. The company earns $-11,020,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Neurotrope employs 6 workers across the globe.View Additional Information About Neurotrope.

What is Neurotrope's official website?

The official website for Neurotrope is http://www.neurotropebioscience.com/.

How can I contact Neurotrope?

Neurotrope's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected]


MarketBeat Community Rating for Neurotrope (NASDAQ NTRP)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  199 (Vote Underperform)
Total Votes:  368
MarketBeat's community ratings are surveys of what our community members think about Neurotrope and other stocks. Vote "Outperform" if you believe NTRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel